Investors Sell Shares of Zoetis Inc. (ZTS) on Strength (ZTS)
Investors sold shares of Zoetis Inc. (NYSE:ZTS) on strength during trading on Friday. $16.82 million flowed into the stock on the tick-up and $38.15 million flowed out of the stock on the tick-down, for a money net flow of $21.33 million out of the stock. Of all equities tracked, Zoetis had the 0th highest net out-flow for the day. Zoetis traded up $0.29 for the day and closed at $50.76
A number of brokerages have commented on ZTS. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Guggenheim reiterated a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Wednesday, May 4th. Citigroup Inc. raised their target price on shares of Zoetis from $50.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Credit Suisse Group AG restated an “outperform” rating and set a $60.00 target price on shares of Zoetis in a research note on Tuesday, August 23rd. Finally, Goldman Sachs Group Inc. cut shares of Zoetis from a “neutral” rating to a “sell” rating and raised their target price for the stock from $46.00 to $48.00 in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $54.79.
The company’s 50-day moving average is $50.61 and its 200-day moving average is $46.65. The stock has a market cap of $25.13 billion and a PE ratio of 39.53.
Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.05. During the same quarter in the previous year, the company earned $0.43 EPS. The firm earned $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. The business’s revenue was up 2.8% compared to the same quarter last year. On average, equities research analysts predict that Zoetis Inc. will post $1.90 earnings per share for the current year.
A hedge fund recently raised its stake in Zoetis stock. Schwab Charles Investment Management Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,491,364 shares of the company’s stock after buying an additional 31,045 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.30% of Zoetis worth $71,467,000 as of its most recent filing with the SEC.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.